Temporal organization of gonadal and adrenal steroid fluctuations in male mice [0.03%]
小鼠生殖腺和肾上腺雄性激素的瞬时节律性波动规律研究
M Chase Kettering,Marion C Hope rd,Christian A Unger et al.
M Chase Kettering et al.
Graphical abstract: Longitudinal arterial sampling combined with LC-MS/MS profiling was used to define the temporal organization of circulating steroid hormones in adult male mice. Adrenal steroids (corticosterone and deo...
Preoperative First-line Amlodipine in Pheochromocytoma/Paraganglioma: Perioperative Haemodynamic Instability and Its Predictors [0.03%]
术前一线使用氨氯地平治疗嗜铬细胞瘤/副神经节瘤的围手术期血流动力学不稳定及其预测因素
Chandramouli L,Saba Samad Memon,Anurag Ranjan Lila et al.
Chandramouli L et al.
Objectives: Preoperative alpha blockade is recommended for pheochromocytomas and paragangliomas (PPGL), whereas evidence for calcium channel blockers (CCBs) remains limited. This study evaluated perioperative haemodynamic...
From patients to partners: Evaluating a co-designed website for congenital hypogonadotropic hypogonadism [0.03%]
从患者到合作伙伴：评估先天性低促性腺激素性性腺功能减退症的协同设计网站
Andrew A Dwyer,Neil Smith,Samantha Strasser et al.
Andrew A Dwyer et al.
Background: Patients with congenital hypogonadotropic hypogonadism (CHH) are geographically dispersed and have unmet health and informational needs. Patients often rely on the internet to learn about CHH, find expert care...
The Effects of Rebound Exercise on Body Mass Index and Balance Among Overweight and Obese Adults: A Meta-Analysis [0.03%]
反弹运动对超重和肥胖成年人体质指数和平衡影响的meta分析研究
Lin Wang,Sihong Sui
Lin Wang
Background: Rebounding involves repetitive bouncing on a trampoline, a low-impact and enjoyable exercise. The purpose of this study was to explore the effects of rebound exercise on body mass index (BMI) and balance in ad...
Additional treatment strategies for Hypothyroidism: A Network Meta-Analysis [0.03%]
亚临床甲状腺功能减退的治疗策略网状meta分析
Xingang Lv,Wentao Qin,Jiarui Li et al.
Xingang Lv et al.
Background: Hypothyroidism often impairs quality of life (QoL). This network meta-analysis (NMA) evaluated the efficacy and safety of additional interventions alongside levothyroxine (LT4). ...
The complex interaction between obesity and puberty and its implications for pubertal timing - A review of recent evidence [0.03%]
肥胖与青春期之间的复杂相互作用及其对青春期时机的影响——近期证据综述
Kettyuscia Coelho E Oliveira,Lucila Leico Kagohara Elias,Sonir R Rauber Antonini
Kettyuscia Coelho E Oliveira
The childhood and adolescent obesity epidemic remain one of the most important and challenging health issues of the 21st century. Excess body weight affects the immediate health of children and adolescents, being associated with a higher an...
Hypoparathyroidism: clinical profiles, healthcare use and costs from real-world data from Italy [0.03%]
意大利真实世界数据中的低甲状旁腺素血症：临床特征、医疗使用和费用
Andrea Palermo,Guido Zavatta,Erica Solaroli et al.
Andrea Palermo et al.
Aim: To describe the epidemiological, clinical, and healthcare profiles of treated hypoparathyroidism in Italy and to evaluate healthcare resources utilization and direct costs. ...
Neural plasticity impairment in chronic post-surgical hypoparathyroidism: a cross-sectional and prospective pilot study [0.03%]
慢性术后继发性低甲状旁腺功能亢进患者神经可塑性的损伤：横断面及前瞻性试点研究
Andrea Palermo,Gaia Tabacco,Anda Mihaela Naciu et al.
Andrea Palermo et al.
Background: Despite adequate conventional therapy, patients with chronic post-surgical hypoparathyroidism(HypoPT) frequently report persistent physical, emotional, and cognitive symptoms that affect quality of life, despi...
Assessment of the 5 Year Evaluation for 1st call members of the European Reference Network on Rare Endocrine Conditions (Endo-ERN) [0.03%]
欧洲罕见内分泌状况参考网络（ERN Endo）首批成员五年评估报告
Emily K White,Tessa de Bruin,Olaf Hiort et al.
Emily K White et al.
Background: The European Reference Networks on Rare Endocrine Diseases (Endo-ERN) and member healthcare provider (HCP)s, both are mandated to undergo periodical evaluation of their performance every 5 years. This evaluati...
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK [0.03%]
司美格鲁肽在英国心血管疾病但无2型糖尿病患者中的预期生命年增量
Thomas van Sloten,Steven H J Hageman,Jan Westerink et al.
Thomas van Sloten et al.
In the SELECT cardiovascular (CV) outcomes trial, semaglutide 2.4 mg significantly reduced all-cause mortality or non-fatal CV events versus placebo in patients with CV disease (CVD) and overweight/obesity, without type 2 diabetes (T2D). By...